Multi-center, blinded, randomised, PaRallEl-group, Phase 3 study with AproCItentan in Subjects with ResIstant HypertensiON (RHT)

The primary objective of this study was to demonstrate the blood pressure (BP) lowering effect of Aprocitentan when added to standard of care in true resistant hypertension (RHT) subjects.

Eligible participants were 18 years or older, with documented uncontrolled BP despite 3 background hypertensive medications with no known secondary causes of hypertension.

Results of the study can be viewed here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02034-7/fulltext

Aprocitentan is currently in pre-registration with the US FDA (Food and Drug Administration).

For further information please phone 1800 971 022